Nanoparticle-Based Immunotherapy Strategies in Oncology

Nanoparticle-based immunotherapy harnesses engineered nanoscale carriers to enhance the specificity, potency and safety of anti-cancer immune responses. By encapsulating tumour antigens, adjuvants or immunomodulatory agents, nanoparticles can protect cargo from degradation, promote targeted delivery to lymphoid organs or tumour sites and modulate the local immune milieu. Strategies include direct lymph node targeting to prime antigen-presenting cells, reshaping the tumour microenvironment through macrophage repolarisation or stromal modulation and co-delivery of checkpoint inhibitors to overcome adaptive resistance. Advanced designs exploit biomimetic coatings, stimuli-responsive release triggered by pH, redox or light and multifunctional platforms combining diagnostic and therapeutic functions. Such nanoarchitectures have demonstrated improved T-cell activation, durable memory responses and synergistic efficacy when combined with existing immunotherapies. Globally, these approaches promise more precise cancer vaccines, lower systemic toxicity and enhanced responses across tumour types, offering a versatile toolkit to address the heterogeneity and immunosuppression that limit current treatments.

Research from Nature Portfolio

Recent studies have introduced self-assembling albumin-binding nanocomplexes that form in vivo to co-deliver CpG adjuvant and tumour antigens, dramatically increasing lymph node uptake and CD8+ T-cell expansion compared with conventional emulsions. Intertwining DNA–RNA nanocapsules have been engineered to carry synergistic CpG, shRNA adjuvants and peptide neoantigens, yielding robust antigen presentation, memory T-cell induction and potent inhibition of antigen-specific tumours. A further innovation employs melittin-lipid nanoparticles that, without exogenous antigens, trigger in situ antigen release and activate antigen-presenting cells in lymph nodes, eliciting systemic CD8+ responses and marked suppression of primary and distant melanoma lesions.

Nanoparticle-Based Immunotherapy Strategies in Oncology publication trend

The graph below shows the total number of articles in nanoparticle-based immunotherapy strategies in oncology across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticle: A synthetic or biomimetic structure with dimensions typically below 200 nm, designed to carry therapeutic or immunological cargo to specific cells or tissues.

Tumour microenvironment (TME): The complex milieu surrounding a tumour, including stromal cells, immune cells, extracellular matrix and signalling molecules that influence tumour growth and immune evasion.

Antigen-presenting cell (APC): A specialised immune cell, such as a dendritic cell or macrophage, that processes and displays antigen fragments to T cells to initiate adaptive immunity.

Biomimetic nanoparticle: A nanoparticle coated or constructed with biological components (e.g., cell membranes, proteins) to mimic native structures and evade immune clearance or target specific cells.

Stimuli-responsive nanocarrier: A nanoparticle engineered to release its payload in response to specific environmental cues (for example, changes in pH, redox potential or light exposure) at the target site.

References

1. Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy. Nano-Micro Letters (2023).
2. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. Journal of Hematology & Oncology (2024).
3. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nature Communications (2017).
4. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy. Nature Communications (2017).
5. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nature Communications (2020).